Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has announced that its nine-valent recombinant human papillomavirus (HPV) vaccine, co-developed with Xiamen University, has received priority review status from China’s Center for Drug Evaluation (CDE).
This vaccine targets seven high-risk HPV types (HPV16, 18, 31, 33, 45, 52, and 58) as well as two low-risk types (HPV6 and 11). The priority review designation underscores the product’s potential significance in advancing public health initiatives aimed at reducing HPV-related diseases in China.- Flcube.com
